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lack evidence on their effectiveness. In 1988 we noted
that lack of outcome evaluation makes it impossible to
judge the effectiveness of these rehabilitation pro-
grammes in facilitating recovery from the trauma of
torture.Unfortunately, evidence is still lacking.A recent
report based on the work of the Rehabilitation and
Research Centre for Torture Victims in Denmark is a
sobering reminder of where we stand after two
decades. The Danish centre is a pioneering organisa-
tion , serving as a model for more than 90 similar cen-
tres around the world. An outcome evaluation study
based on 55 people admitted to the centre in 2001 and
2002 showed no improvement in post-traumatic stress
disorder, depression, anxiety, or health-related quality
of life after nine months’ treatment.12 These findings
led the authors to conclude that future studies are
needed to explore effective in terventions for trauma-
tised refugees, including cognitive behavioural therapy.
This is indeed what we had recommended in1988.1
Lack of progress among torture survivors par tly
stems from the fact that scien tific approaches to the
problem are often dismissed as reductionist “medical-
ising.” Many of those working with tor ture survivors
advocate a solely political approach to the problem in
the belief that recovery from trauma is only possible
through eradicating impunity for the perpetrators of
torture. Research evidence does not support th is view.3
Although advocacy against tor ture is certain ly impor-
tan t, as long as the problem lasts rehabilitation centres
also have a moral obligation to provide effective
psychological treatment for their clients. After more
than 30 years of work, those working with torture sur-
vivors need to confront the uneasy but important
question of whether their approach is helpful. This
issue can be addressed only by proper outcome evalu-
ation. Given that there are now very brief and highly
effective interventions available for survivors, the pub-
lic have a right to know the justification behind lengthy
and expensive rehabilitation programmes without
demonstrable beneficial effects.
Funders of rehabilitation programmes are in an
excellent position to promote progress here. They also
need to adopt an evidence-based approach and
consider the following questions in their review of fund-
ing applications: (a) is the proposed intervention based
on sound theory; (b) is there is sufficient evidence on its
effectiveness; and (c) does the work involve outcome
evaluation? Making grant support conditional on such
requirements would certainly enhance the quality of
work in the field. Given the painfully slow progress this
appears to be the only hope for change.
Metin Bas¸og˘lu head of trauma studies unit
(spjumeb@iop.kcl.ac.uk)
Institute of Psychiatry, King’s College, London
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The Cooksey review of UK health research fund ing
The art of being all things to all people
Prompted by concern that the drug industrymight reduce its investment in research in theUnited Kingdom, the chancellor of the exche-
quer asked the distinguished venture capitalist Sir
David Cooksey to lead a review. Widespread consulta-
tion showed that it is not only the Treasury that is con-
cerned about the current state of health research
funding, organisation, and performance.1
Four principal criticisms emerged. Firstly (confirm-
ing the Treasury’s view), the drug industry is frustrated
by what it sees as increasing obstacles to gaining access
to patien ts and over-regulation leading to unaccept-
able delays and extra costs. Companies claim that
developing products and conducting research in other
countries is increasingly attractive and an inevitable
consequence. Secondly, those responsible for provid-
ing health services—politicians, managers, clin icians—
as well as research funders are concerned at the delays
in translating advances in basic science into clinical
applications and then translating such innovations in to
routine practice. This is seen as reflecting an
unsupportive culture in the National Health Service,
institutional barriers, and perverse incentives, such as
greater regard and reward for basic research than for
applied research . Thirdly, the distribution of research
funds does not always reflect the burden of disease in
the UK,which reflects the lack of a transparent mecha-
nism for determining research priorities. This is par tly
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explained by the final concern that Cooksey
identified—the lack of coordination and a supposed
resulting inefficiency between the principal funding
bodies and, in particular, the two public funders, the
Medical Research Council (MRC) and the NHS
National Institute for Health Research (NIHR).
Together with criticisms came solutions. Faced with
more than 300 responses from individuals and organi-
sations, each with their own interests to defend and
promote, the review team have constructed a strategy
that tries to deal with the four principal concerns.
Given the disparate nature of those concerns, the strat-
egy is a masterful attempt at coherence.
The concerns of the drug industry (and the
Treasury) are to be met by bringing new drugs to
market faster, without compromising patien t safety,
and more cheaply.A new “drug development pathway”
will include streamlining clin ical trial procedures,
“conditional licensing,” earlier involvement of the
National Institute for Health and Clinical Excellence
(NICE), and ensuring NICE’s recommendations are
implemented. The aim is to “send a signal to industry
that the UK is a world leader in research and
development. ”
The challenge of promoting translation is to be met
in several ways. The recently ring fenced budget for the
NIHR is seen as a useful development though other
funds, such as research training budgets for young
clin icians, need to be brought inside the fence. More
funding for the NHS Health Technology Assessment
programme is proposed, together with the creation of
a new Translational Medicine Funding Board, account-
able to the NIHR and MRC. All of these initiatives are
seen as par t of creating a stronger research culture in
the NHS that facilitates rather than discourages
innovation .
To encourage greater atten tion to currently unmet
health needs, research on neglected areas will be iden-
tified through burden of illness analyses, and
designated topics will be labelled as UK Priority Health
Research Projects. Public, private, and charitable
research funders will hopefully respond to the institu-
tional and procedural advantages that such priorities
will benefit from, such as faster approval of trials and
expedited approval from NICE.
The final criticism of the status quo, namely lack of
coordination between public funders, is the one that
has probably attracted the greatest interest, concern,
and often heated debate. The proposed solution is to
strengthen coordination by establishing an overarch-
ing O ffice for Strategic Coordination of Health
Research (OSCHR, pronounced “O scar”) that is
accountable to both the Department of Health and the
Department of Trade and Industry. Its tasks include
setting a health research strategy that both the MRC
and NIHR must comply with, agreeing their funding
needs, submitting those needs to the Treasury, and
monitoring the results. To reduce duplication , some
areas currently funded by MRC (including clin ical
research, health services research, and phase IV clin ical
trials) will become the sole responsibility of the NIHR
so that the MRC can concentrate on basic and under-
pinning research. In addition , some structural changes
are advocated—members of MRC boards are expected
to become more representative of the broad spectrum
of health research while the NIHR should become a
real, rather than a vir tual, institute and be separated
from the Department of Health from 2009 as an
executive agency.
Cooksey’s proposals, which the government has
welcomed and accepted, are in the great tradition of
compromise solutions. The two major public funders,
MRC and NIHR, are to work more closely, but a th ird
public funding stream is to be created; more funding
will be provided for translational research but funds for
basic research will not be reduced; “blue skies” investi-
gator led research will continue to be supported but
national research priorities will be instigated. Anyone
wanting and expecting more radical change to the
structure and processes of research funding will be dis-
appointed.Merger of the MRC and NIHR was rejected
because of a fear that the larger MRC would dominate,
and that th is would jeopardise the development of
translational and applied research .
Although, potentially, there is something for every-
one in the overall package of proposals, for several rea-
sons its success is not guaranteed. Firstly, the review is
predicated on the view that we stand on the threshold
of “a seismic shift in medical science” in which molecu-
lar medicine, gene therapy, stem cells, and other initia-
tives will revolutionise health care. Such faith in
technology as the principal driver of improvements in
people’s health may prove over optimistic. Secondly,
while the strategy shares much in common with
reforms enacted in Canada in recent years, their
success was facilitated by a 130% increase in research
funds over five years, a level of investment not
envisaged in the UK. Thirdly, key aspects depend on
private industry responding to new incentives. O n the
one hand, the sorts of incentives that might motivate
public researchers, such as those associated with Prior-
ity Health Research Projects, may be insufficien t to
influence private companies. O n the other hand, there
is a danger that incentives offered to private industry in
which they can dictate the agenda of NICE and the
Health Technology Assessment programme risks
those bodies being co-opted and becoming adjuncts of
the drug industry.2 And lastly, while the strategy
involves some straightforward structural changes that
can be implemented from the centre, much of it relies
on widespread cultural and behavioural changes
with in the NHS and research community,which will be
hard to ensure take place.
Much also depends on the alignment of other poli-
cies such as those concerned with NHS finance,
research assessment exercises, and postgraduate train-
ing. Perhaps it is for these reasons that Cooksey recog-
nises the need to review progress in 2010.
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